

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: PAT1/21 - Direct Antiglobulin Test

Deadline: 04.06.2021

| | | |
|------|---|---|
| Key: | >>> ... marks correct (expected) result | N ... number of the results |
| | > ... marks conditionally correct (acceptable) result | Nrel ... relative number of the results |
| | ± ... marks the result not evaluated | |

Test

| Sample | Group | N | Result | N _{rel} |
|--|---------------------------------|----------------|------------------|------------------|
| (1001) DAT (direct Coombs test) | | | | |
| 1 | (14) Bio-Rad | > | 26 Negative | 31 % |
| | | >>> | 20 Positive (1+) | 24 % |
| | (17) Biogema | > | 1 Negative | 1,2 % |
| | (40) Ortho Clinical Diagnostics | >>> | 3 Positive (1+) | 3,5 % |
| | | > | 1 Positive (2+) | 1,2 % |
| | (80) DiaMed | > | 5 Negative | 5,9 % |
| | | >>> | 5 Positive (1+) | 5,9 % |
| | | > | 1 Positive (3+) | 1,2 % |
| | (159) Grifols | > | 7 Negative | 8,2 % |
| | | >>> | 14 Positive (1+) | 16 % |
| | | > | 1 Positive (2+) | 1,2 % |
| | (173) Sanguin | > | 1 Negative | 1,2 % |
| ----- Total per sample: n = 85 ----- | | Success: 100 % | ----- | |
| 2 | (14) Bio-Rad | >>> | 31 Positive (3+) | 36 % |
| | | > | 15 Positive (4+) | 18 % |
| | (17) Biogema | >>> | 1 Positive (3+) | 1,2 % |
| | (40) Ortho Clinical Diagnostics | >>> | 2 Positive (3+) | 2,4 % |
| | | > | 2 Positive (4+) | 2,4 % |
| | (80) DiaMed | | 1 Negative | 1,2 % |
| | | > | 1 Positive (2+) | 1,2 % |
| | | >>> | 2 Positive (3+) | 2,4 % |
| | | > | 7 Positive (4+) | 8,2 % |
| | (159) Grifols | >>> | 9 Positive (3+) | 11 % |
| | | > | 13 Positive (4+) | 15 % |
| | (173) Sanguin | > | 1 Positive (2+) | 1,2 % |
| ----- Total per sample: n = 85 ----- | | Success: 99 % | ----- | |
| Total success: 99 % | | | | |

(1002) Sensitization specificity anti-IgG

| | | | | |
|--------------------------------------|-------------------|----------------|------------------|-------|
| 1 | (0) not specified | >>> | 1 Negative | 2,4 % |
| | (14) Bio-Rad | >>> | 20 Negative | 49 % |
| | | > | 3 Positive (1+) | 7,3 % |
| | (80) DiaMed | > | 1 Not specified | 2,4 % |
| | | >>> | 6 Negative | 15 % |
| | | > | 2 Positive (1+) | 4,9 % |
| | (159) Grifols | >>> | 6 Negative | 15 % |
| | | > | 1 Positive (1+) | 2,4 % |
| | | > | 1 Positive (2+) | 2,4 % |
| ----- Total per sample: n = 41 ----- | | Success: 100 % | ----- | |
| 2 | (0) not specified | >>> | 1 Positive (3+) | 2,4 % |
| | (14) Bio-Rad | >>> | 15 Positive (3+) | 37 % |
| | | > | 8 Positive (4+) | 20 % |
| | (80) DiaMed | > | 1 Positive (2+) | 2,4 % |
| | | >>> | 1 Positive (3+) | 2,4 % |
| | | > | 7 Positive (4+) | 17 % |
| | (159) Grifols | >>> | 4 Positive (3+) | 9,8 % |
| | | > | 4 Positive (4+) | 9,8 % |
| ----- Total per sample: n = 41 ----- | | Success: 100 % | ----- | |
| Total success: 100 % | | | | |

(1003) Sensitization specificity anti-IgA

| | | | | |
|--------------------------------------|--------------|----------------|-----------------|-------|
| 1 | (14) Bio-Rad | >>> | 22 Negative | 71 % |
| | (80) DiaMed | > | 1 Not specified | 3,2 % |
| | | >>> | 8 Negative | 26 % |
| ----- Total per sample: n = 31 ----- | | Success: 100 % | ----- | |
| 2 | (14) Bio-Rad | >>> | 22 Negative | 71 % |
| | (80) DiaMed | >>> | 9 Negative | 29 % |
| ----- Total per sample: n = 31 ----- | | Success: 100 % | ----- | |
| Total success: 100 % | | | | |

(1004) Sensitization specificity anti-IgM

| | | | | |
|---|--------------|-----|------------------|-------|
| 1 | (14) Bio-Rad | | 3 Negative | 9,7 % |
| | | > | 13 Positive (1+) | 42 % |
| | | >>> | 6 Positive (2+) | 19 % |
| | (80) DiaMed | > | 1 Not specified | 3,2 % |
| | | | 1 Negative | 3,2 % |
| | | > | 5 Positive (1+) | 16 % |

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: PAT1/21 - Direct Antiglobulin Test

Deadline: 04.06.2021

| Test | Sample | Group | N | Result | N _{rel} |
|--|--------------------------|----------------|-----------------|-----------------|------------------|
| 1 | (80) DiaMed | >>> | 2 | Positive (2+) | 6,5 % |
| | Total per sample: n = 31 | | Success: 87 % | | |
| 2 | (14) Bio-Rad | >>> | 22 | Negative | 71 % |
| | (80) DiaMed | >>> | 9 | Negative | 29 % |
| Total per sample: n = 31 | | Success: 100 % | | | |
| Total success: 87 % | | | | | |
| (1005) Sensitization specificity anti-C3c | | | | | |
| 1 | (0) not specified | >>> | 1 | Negative | 3,1 % |
| | (14) Bio-Rad | >>> | 22 | Negative | 69 % |
| | (80) DiaMed | > | 1 | Not specified | 3,1 % |
| | Total per sample: n = 32 | | Success: 100 % | 8 Negative | 25 % |
| 2 | (0) not specified | >>> | 1 | Negative | 3,1 % |
| | (14) Bio-Rad | >>> | 22 | Negative | 69 % |
| | (80) DiaMed | >>> | 9 | Negative | 28 % |
| | Total per sample: n = 32 | | Success: 100 % | | |
| Total success: 100 % | | | | | |
| (1006) Sensitization specificity anti-C3d | | | | | |
| 1 | (14) Bio-Rad | >>> | 23 | Negative | 62 % |
| | (80) DiaMed | > | 2 | Not specified | 5,4 % |
| | (159) Grifols | >>> | 8 | Negative | 22 % |
| | Total per sample: n = 37 | | Success: 100 % | 3 Negative | 8,1 % |
| 2 | (14) Bio-Rad | >>> | 23 | Negative | 62 % |
| | (80) DiaMed | >>> | 10 | Negative | 27 % |
| | (159) Grifols | >>> | 4 | Negative | 11 % |
| | Total per sample: n = 37 | | Success: 100 % | 1 Positive (1+) | 2,7 % |
| Total success: 100 % | | | | | |
| (1008) Col. agglut: Quantif. IgG-DAT | | | | | |
| 1 | (14) Bio-Rad | > | 4 | Not specified | 17 % |
| | (80) DiaMed | >>> | 13 | Negative | 54 % |
| | (80) DiaMed | > | 2 | Not specified | 8,3 % |
| | Total per sample: n = 24 | | Success: 100 % | 5 Negative | 21 % |
| 2 | (14) Bio-Rad | > | 1 | 1:10 | 4,2 % |
| | (80) DiaMed | >>> | 12 | 1:100 | 50 % |
| | (80) DiaMed | > | 4 | 1:300 | 17 % |
| | Total per sample: n = 24 | | Success: 100 % | 5 1:100 | 21 % |
| | | | 2 1:300 | 8,3 % | |
| Total success: 100 % | | | | | |
| (1009) Col. agglut: Subclass IgG1 1:1 | | | | | |
| 1 | (14) Bio-Rad | > | 3 | Not specified | 14 % |
| | (80) DiaMed | >>> | 12 | Negative | 55 % |
| | (80) DiaMed | > | 2 | Not specified | 9,1 % |
| | Total per sample: n = 22 | | Success: 100 % | 5 Negative | 23 % |
| 2 | (14) Bio-Rad | >>> | 1 | Negative | 4,5 % |
| | (80) DiaMed | >>> | 11 | Positive (1+) | 50 % |
| | (80) DiaMed | > | 3 | Positive (2+) | 14 % |
| | Total per sample: n = 22 | | Success: 95 % | 6 Positive (1+) | 27 % |
| | | | 1 Positive (2+) | 4,5 % | |
| Total success: 95 % | | | | | |
| (1010) Col. agglut: Subclass IgG1 1:100 | | | | | |
| 1 | (14) Bio-Rad | > | 3 | Not specified | 14 % |
| | (80) DiaMed | >>> | 12 | Negative | 55 % |
| | (80) DiaMed | > | 2 | Not specified | 9,1 % |
| | Total per sample: n = 22 | | Success: 100 % | 5 Negative | 23 % |
| 2 | (14) Bio-Rad | >>> | 15 | Negative | 68 % |
| | (80) DiaMed | >>> | 7 | Negative | 32 % |
| Total per sample: n = 22 | | Success: 100 % | | | |
| Total success: 100 % | | | | | |
| (1011) Col. agglut: Subclass IgG3 1:1 | | | | | |

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: PAT1/21 - Direct Antiglobulin Test

Deadline: 04.06.2021

| Test | Sample | Group | N | Result | N _{rel} |
|---------------------|--------------|--------------------------|-----|-----------------|------------------|
| 1 | (14) Bio-Rad | | > | 3 Not specified | 14 % |
| | | | >>> | 12 Negative | 55 % |
| | (80) DiaMed | | > | 2 Not specified | 9,1 % |
| | | | >>> | 5 Negative | 23 % |
| | | Total per sample: n = 22 | | Success: 100 % | |
| 2 | (14) Bio-Rad | | >>> | 14 Negative | 64 % |
| | | | | 1 Positive (2+) | 4,5 % |
| | (80) DiaMed | | >>> | 5 Negative | 23 % |
| | | | | 2 Positive (1+) | 9,1 % |
| | | Total per sample: n = 22 | | Success: 86 % | |
| Total success: 86 % | | | | | |

(1012) Col. agglut: Subclass IgG3 1:100

| | | | | | |
|----------------------|--------------------------|--------------------------|----------------|-----------------|-------|
| 1 | (14) Bio-Rad | | > | 3 Not specified | 14 % |
| | | | >>> | 12 Negative | 55 % |
| | (80) DiaMed | | > | 2 Not specified | 9,1 % |
| | | | >>> | 5 Negative | 23 % |
| | | Total per sample: n = 22 | | Success: 100 % | |
| 2 | (14) Bio-Rad | | >>> | 15 Negative | 68 % |
| | (80) DiaMed | | >>> | 7 Negative | 32 % |
| | Total per sample: n = 22 | | Success: 100 % | | |
| Total success: 100 % | | | | | |

(1019) AB0 blood group

| | | | | | |
|----------------------|---------------------------------|--|----------------|--------------------|-------|
| 1 | (14) Bio-Rad | | >>> | 20 Blood group: B | 36 % |
| | (40) Ortho Clinical Diagnostics | | >>> | 3 Blood group: B | 5,4 % |
| | (64) Exbio Olomouc | | >>> | 1 Blood group: B | 1,8 % |
| | (80) DiaMed | | >>> | 2 Blood group: B | 3,6 % |
| | (159) Grifols | | >>> | 13 Blood group: B | 23 % |
| | (172) Immucor | | >>> | 5 Blood group: B | 8,9 % |
| | (173) Sanguin | | >>> | 7 Blood group: B | 13 % |
| | (174) IVT Imuno | | >>> | 4 Blood group: B | 7,1 % |
| | (183) Immunodiagnostic Systems | | >>> | 1 Blood group: B | 1,8 % |
| | Total per sample: n = 56 | | Success: 100 % | | |
| 2 | (14) Bio-Rad | | >>> | 20 Blood group: AB | 36 % |
| | (40) Ortho Clinical Diagnostics | | >>> | 3 Blood group: AB | 5,4 % |
| | (64) Exbio Olomouc | | >>> | 1 Blood group: AB | 1,8 % |
| | (80) DiaMed | | >>> | 2 Blood group: AB | 3,6 % |
| | (159) Grifols | | >>> | 13 Blood group: AB | 23 % |
| | (172) Immucor | | >>> | 5 Blood group: AB | 8,9 % |
| | (173) Sanguin | | >>> | 7 Blood group: AB | 13 % |
| | (174) IVT Imuno | | >>> | 4 Blood group: AB | 7,1 % |
| | (183) Immunodiagnostic Systems | | >>> | 1 Blood group: AB | 1,8 % |
| | Total per sample: n = 56 | | Success: 100 % | | |
| Total success: 100 % | | | | | |

(1020) Rh D antigen

| | | | | | |
|--------------------------------|---------------------------------|---------------------------------|-------------------|--------------------------|-------------------|
| 1 | (14) Bio-Rad | | >>> | 24 Negative (RhD-) | 43 % |
| | | (40) Ortho Clinical Diagnostics | | >>> | 2 Negative (RhD-) |
| | | | | 1 w/v (RhD weak/variant) | 1,8 % |
| | | | | 1 Negative (RhD-) | 1,8 % |
| | (52) Dynex | | >>> | 1 Negative (RhD-) | 1,8 % |
| | (64) Exbio Olomouc | | >>> | 1 Negative (RhD-) | 1,8 % |
| | (80) DiaMed | | | 1 Not specified | 1,8 % |
| | | | >>> | 1 Negative (RhD-) | 1,8 % |
| | (159) Grifols | | >>> | 12 Negative (RhD-) | 21 % |
| | | | | 1 w/v (RhD weak/variant) | 1,8 % |
| | | | >>> | 1 Negative (RhD-) | 1,8 % |
| | (170) Biotest | | >>> | 4 Negative (RhD-) | 7,1 % |
| | (172) Immucor | | >>> | 5 Negative (RhD-) | 8,9 % |
| | (173) Sanguin | | >>> | 1 Negative (RhD-) | 1,8 % |
| | (174) IVT Imuno | | >>> | 1 Negative (RhD-) | 1,8 % |
| (183) Immunodiagnostic Systems | | >>> | 1 Negative (RhD-) | 1,8 % | |
| Total per sample: n = 56 | | Success: 95 % | | | |
| 2 | (14) Bio-Rad | | >>> | 24 Positive (RhD+) | 43 % |
| | (40) Ortho Clinical Diagnostics | | >>> | 3 Positive (RhD+) | 5,4 % |
| | (52) Dynex | | >>> | 1 Positive (RhD+) | 1,8 % |
| | (64) Exbio Olomouc | | >>> | 1 Positive (RhD+) | 1,8 % |
| | (80) DiaMed | | >>> | 2 Positive (RhD+) | 3,6 % |
| | (159) Grifols | | >>> | 13 Positive (RhD+) | 23 % |
| | (170) Biotest | | >>> | 1 Positive (RhD+) | 1,8 % |
| | (172) Immucor | | >>> | 4 Positive (RhD+) | 7,1 % |
| | (173) Sanguin | | >>> | 5 Positive (RhD+) | 8,9 % |

EQA round: PAT1/21 - Direct Antiglobulin Test

Deadline: 04.06.2021

| Test | Sample | Group | N | Result | N _{rel} |
|---|--------|--------------------------------|-----|-------------------|------------------|
| | 2 | (174) IVT Imuno | >>> | 1 Positive (RhD+) | 1,8 % |
| | | (183) Immunodiagnostic Systems | >>> | 1 Positive (RhD+) | 1,8 % |
| ----- Total per sample: n = 56 ----- Success: 100 % ----- | | | | | |
| Total success: 95 % | | | | | |

(1021) Antigen C

| | | | | | |
|---|--------------------------------|-----|----|----------|-------|
| 1 | (14) Bio-Rad | >>> | 16 | Negative | 36 % |
| | (80) DiaMed | >>> | 3 | Negative | 6,8 % |
| | (159) Grifols | >>> | 17 | Negative | 39 % |
| | (172) Immucor | >>> | 3 | Negative | 6,8 % |
| | (173) Sanguin | >>> | 3 | Negative | 6,8 % |
| | (183) Immunodiagnostic Systems | >>> | 1 | Negative | 2,3 % |
| | (999) another manufacturer | >>> | 1 | Negative | 2,3 % |
| ----- Total per sample: n = 44 ----- Success: 100 % ----- | | | | | |
| 2 | (14) Bio-Rad | >>> | 16 | Positive | 36 % |
| | (80) DiaMed | >>> | 3 | Positive | 6,8 % |
| | (159) Grifols | >>> | 17 | Positive | 39 % |
| | (172) Immucor | >>> | 3 | Positive | 6,8 % |
| | (173) Sanguin | >>> | 3 | Positive | 6,8 % |
| | (183) Immunodiagnostic Systems | >>> | 1 | Positive | 2,3 % |
| | (999) another manufacturer | >>> | 1 | Positive | 2,3 % |
| ----- Total per sample: n = 44 ----- Success: 100 % ----- | | | | | |
| Total success: 100 % | | | | | |

(1022) Antigen c

| | | | | | |
|---|--------------------------------|-----|----|----------|-------|
| 1 | (14) Bio-Rad | >>> | 16 | Positive | 36 % |
| | (80) DiaMed | >>> | 3 | Positive | 6,8 % |
| | (159) Grifols | >>> | 17 | Positive | 39 % |
| | (172) Immucor | >>> | 3 | Positive | 6,8 % |
| | (173) Sanguin | >>> | 3 | Positive | 6,8 % |
| | (183) Immunodiagnostic Systems | >>> | 1 | Positive | 2,3 % |
| | (999) another manufacturer | >>> | 1 | Positive | 2,3 % |
| ----- Total per sample: n = 44 ----- Success: 100 % ----- | | | | | |
| 2 | (14) Bio-Rad | >>> | 16 | Positive | 36 % |
| | (80) DiaMed | >>> | 3 | Positive | 6,8 % |
| | (159) Grifols | >>> | 17 | Positive | 39 % |
| | (172) Immucor | >>> | 3 | Positive | 6,8 % |
| | (173) Sanguin | >>> | 3 | Positive | 6,8 % |
| | (183) Immunodiagnostic Systems | >>> | 1 | Positive | 2,3 % |
| | (999) another manufacturer | >>> | 1 | Positive | 2,3 % |
| ----- Total per sample: n = 44 ----- Success: 100 % ----- | | | | | |
| Total success: 100 % | | | | | |

(1023) Antigen Cw

| | | | | | |
|--|----------------------------|-----|----|----------|-------|
| 1 | (14) Bio-Rad | >>> | 5 | Negative | 14 % |
| | (159) Grifols | >>> | 18 | Negative | 50 % |
| | (170) Biotest | >>> | 1 | Negative | 2,8 % |
| | (172) Immucor | >>> | 3 | Negative | 8,3 % |
| | (173) Sanguin | >>> | 7 | Negative | 19 % |
| | (174) IVT Imuno | >>> | 1 | Positive | 2,8 % |
| | (999) another manufacturer | >>> | 1 | Negative | 2,8 % |
| ----- Total per sample: n = 36 ----- Success: 97 % ----- | | | | | |
| 2 | (14) Bio-Rad | >>> | 5 | Negative | 14 % |
| | (159) Grifols | >>> | 18 | Negative | 50 % |
| | (170) Biotest | >>> | 1 | Negative | 2,8 % |
| | (172) Immucor | >>> | 3 | Negative | 8,3 % |
| | (173) Sanguin | >>> | 6 | Negative | 17 % |
| | | >>> | 1 | Positive | 2,8 % |
| | (174) IVT Imuno | >>> | 1 | Negative | 2,8 % |
| | (999) another manufacturer | >>> | 1 | Negative | 2,8 % |
| ----- Total per sample: n = 36 ----- Success: 97 % ----- | | | | | |
| Total success: 94 % | | | | | |

(1024) Antigen E

| | | | | | |
|---|--------------------------------|-----|----|----------|-------|
| 1 | (14) Bio-Rad | >>> | 16 | Negative | 36 % |
| | (80) DiaMed | >>> | 3 | Negative | 6,8 % |
| | (159) Grifols | >>> | 17 | Negative | 39 % |
| | (172) Immucor | >>> | 3 | Negative | 6,8 % |
| | (173) Sanguin | >>> | 3 | Negative | 6,8 % |
| | (183) Immunodiagnostic Systems | >>> | 1 | Negative | 2,3 % |
| | (999) another manufacturer | >>> | 1 | Negative | 2,3 % |

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: PAT1/21 - Direct Antiglobulin Test

Deadline: 04.06.2021

| Test | Sample | Group | N | Result | N _{rel} |
|----------------------|--------------------------|--------------------------|----------------|----------|------------------|
| | Total per sample: n = 44 | | Success: 100 % | | |
| 2 | (14) | Bio-Rad | >>> 16 | Positive | 36 % |
| | (80) | DiaMed | >>> 3 | Positive | 6,8 % |
| | (159) | Grifols | >>> 17 | Positive | 39 % |
| | (172) | Immucor | >>> 3 | Positive | 6,8 % |
| | (173) | Sanguin | >>> 3 | Positive | 6,8 % |
| | (183) | Immunodiagnostic Systems | >>> 1 | Positive | 2,3 % |
| | (999) | another manufacturer | >>> 1 | Positive | 2,3 % |
| | Total per sample: n = 44 | | Success: 100 % | | |
| Total success: 100 % | | | | | |

(1025) Antigen e

| | | | | | |
|----------------------|--------------------------|--------------------------|----------------|----------|-------|
| 1 | (14) | Bio-Rad | >>> 16 | Positive | 36 % |
| | (80) | DiaMed | >>> 3 | Positive | 6,8 % |
| | (159) | Grifols | >>> 17 | Positive | 39 % |
| | (172) | Immucor | >>> 3 | Positive | 6,8 % |
| | (173) | Sanguin | >>> 3 | Positive | 6,8 % |
| | (183) | Immunodiagnostic Systems | >>> 1 | Positive | 2,3 % |
| | (999) | another manufacturer | >>> 1 | Positive | 2,3 % |
| | Total per sample: n = 44 | | Success: 100 % | | |
| 2 | (14) | Bio-Rad | >>> 16 | Positive | 36 % |
| | (80) | DiaMed | >>> 3 | Positive | 6,8 % |
| | (159) | Grifols | >>> 17 | Positive | 39 % |
| | (172) | Immucor | >>> 3 | Positive | 6,8 % |
| | (173) | Sanguin | >>> 3 | Positive | 6,8 % |
| | (183) | Immunodiagnostic Systems | >>> 1 | Positive | 2,3 % |
| | (999) | another manufacturer | >>> 1 | Positive | 2,3 % |
| | Total per sample: n = 44 | | Success: 100 % | | |
| Total success: 100 % | | | | | |

(1026) Antigen K

| | | | | | |
|---------------------|--------------------------|--------------------------|----------------|------------|-------|
| 1 | (14) | Bio-Rad | >>> 15 | Negative | 33 % |
| | | | | 1 Positive | 2,2 % |
| | (80) | DiaMed | >>> 2 | Negative | 4,3 % |
| | (159) | Grifols | >>> 19 | Negative | 41 % |
| | (172) | Immucor | >>> 3 | Negative | 6,5 % |
| | (173) | Sanguin | >>> 3 | Negative | 6,5 % |
| | (174) | IVT Imuno | >>> 1 | Negative | 2,2 % |
| | (183) | Immunodiagnostic Systems | >>> 1 | Negative | 2,2 % |
| | (999) | another manufacturer | >>> 1 | Negative | 2,2 % |
| | Total per sample: n = 46 | | Success: 98 % | | |
| 2 | (14) | Bio-Rad | >>> 16 | Negative | 35 % |
| | (80) | DiaMed | >>> 2 | Negative | 4,3 % |
| | (159) | Grifols | >>> 19 | Negative | 41 % |
| | (172) | Immucor | >>> 3 | Negative | 6,5 % |
| | (173) | Sanguin | >>> 3 | Negative | 6,5 % |
| | (174) | IVT Imuno | >>> 1 | Negative | 2,2 % |
| | (183) | Immunodiagnostic Systems | >>> 1 | Negative | 2,2 % |
| | (999) | another manufacturer | >>> 1 | Negative | 2,2 % |
| | Total per sample: n = 46 | | Success: 100 % | | |
| Total success: 98 % | | | | | |

(1027) Antigen k

| | | | | | |
|---------------------|--------------------------|---------------|----------------|---------------|-------|
| 1 | (14) | Bio-Rad | >>> 5 | Positive | 20 % |
| | (64) | Exbio Olomouc | >>> 2 | Positive | 8,0 % |
| | (80) | DiaMed | >>> 3 | Positive | 12 % |
| | (159) | Grifols | >>> 1 | Positive | 4,0 % |
| | (172) | Immucor | >>> 2 | Positive | 8,0 % |
| | (173) | Sanguin | >>> 12 | Positive | 48 % |
| | Total per sample: n = 25 | | Success: 100 % | | |
| 2 | (14) | Bio-Rad | >>> 5 | Positive | 20 % |
| | (64) | Exbio Olomouc | >>> 2 | Positive | 8,0 % |
| | (80) | DiaMed | >>> 1 | Not specified | 4,0 % |
| | | | >>> 2 | Positive | 8,0 % |
| | (159) | Grifols | >>> 1 | Positive | 4,0 % |
| | (172) | Immucor | >>> 2 | Positive | 8,0 % |
| | (173) | Sanguin | >>> 12 | Positive | 48 % |
| | Total per sample: n = 25 | | Success: 96 % | | |
| Total success: 96 % | | | | | |

(1028) Antigen M

| | | | | | |
|---|-----|-----|-------|----------|-------|
| 1 | (6) | APR | >>> 1 | Positive | 4,0 % |
|---|-----|-----|-------|----------|-------|

EQA round: PAT1/21 - Direct Antiglobulin Test

Deadline: 04.06.2021

| Test | Sample | Group | N | Result | N _{rel} | |
|--------------------------|-----------|--------------------------|----------------|----------|------------------|-------|
| 1 | (14) | Bio-Rad | >>> | 3 | Positive | 12 % |
| | (64) | Exbio Olomouc | >>> | 2 | Positive | 8,0 % |
| | (80) | DiaMed | >>> | 2 | Positive | 8,0 % |
| | (159) | Grifols | >>> | 3 | Positive | 12 % |
| | (172) | Immucor | >>> | 6 | Positive | 24 % |
| | (173) | Sanguin | >>> | 4 | Positive | 16 % |
| | (174) | IVT Imuno | >>> | 1 | Positive | 4,0 % |
| | (183) | Immunodiagnostic Systems | >>> | 1 | Positive | 4,0 % |
| | (203) | ANTITOXIN | >>> | 2 | Positive | 8,0 % |
| Total per sample: n = 25 | | | Success: 100 % | | | |
| 2 | (6) | APR | >>> | 1 | Positive | 4,0 % |
| | (14) | Bio-Rad | >>> | 3 | Positive | 12 % |
| | (64) | Exbio Olomouc | >>> | 2 | Positive | 8,0 % |
| | (80) | DiaMed | >>> | 2 | Positive | 8,0 % |
| | (159) | Grifols | >>> | 3 | Positive | 12 % |
| | (172) | Immucor | >>> | 6 | Positive | 24 % |
| | (173) | Sanguin | >>> | 4 | Positive | 16 % |
| | (174) | IVT Imuno | >>> | 1 | Positive | 4,0 % |
| | (183) | Immunodiagnostic Systems | >>> | 1 | Positive | 4,0 % |
| (203) | ANTITOXIN | >>> | 2 | Positive | 8,0 % | |
| Total per sample: n = 25 | | | Success: 100 % | | | |
| Total success: 100 % | | | | | | |

(1029) Antigen N

| | | | | | | |
|--------------------------|-----------|--------------------------|----------------|----------|----------|-------|
| 1 | (6) | APR | >>> | 1 | Negative | 4,3 % |
| | (14) | Bio-Rad | >>> | 3 | Negative | 13 % |
| | (64) | Exbio Olomouc | >>> | 2 | Negative | 8,7 % |
| | (80) | DiaMed | >>> | 2 | Negative | 8,7 % |
| | (159) | Grifols | >>> | 3 | Negative | 13 % |
| | (172) | Immucor | >>> | 4 | Negative | 17 % |
| | (173) | Sanguin | >>> | 4 | Negative | 17 % |
| | (174) | IVT Imuno | >>> | 1 | Negative | 4,3 % |
| | (183) | Immunodiagnostic Systems | >>> | 1 | Negative | 4,3 % |
| (203) | ANTITOXIN | >>> | 2 | Negative | 8,7 % | |
| Total per sample: n = 23 | | | Success: 100 % | | | |
| 2 | (6) | APR | >>> | 1 | Positive | 4,3 % |
| | (14) | Bio-Rad | >>> | 3 | Positive | 13 % |
| | (64) | Exbio Olomouc | >>> | 2 | Positive | 8,7 % |
| | (80) | DiaMed | >>> | 2 | Positive | 8,7 % |
| | (159) | Grifols | >>> | 3 | Positive | 13 % |
| | (172) | Immucor | >>> | 4 | Positive | 17 % |
| | (173) | Sanguin | >>> | 4 | Positive | 17 % |
| | (174) | IVT Imuno | >>> | 1 | Positive | 4,3 % |
| | (183) | Immunodiagnostic Systems | >>> | 1 | Positive | 4,3 % |
| (203) | ANTITOXIN | >>> | 2 | Positive | 8,7 % | |
| Total per sample: n = 23 | | | Success: 100 % | | | |
| Total success: 100 % | | | | | | |

(1030) Antigen S

| | | | | | | |
|--------------------------|--------------------------|--------------------------|----------------|----------------|----------|-------|
| 1 | (6) | APR | >>> | 1 | Positive | 4,0 % |
| | (14) | Bio-Rad | >>> | 2 | Positive | 8,0 % |
| | (64) | Exbio Olomouc | >>> | 2 | Positive | 8,0 % |
| | (80) | DiaMed | >>> | 2 | Positive | 8,0 % |
| | (159) | Grifols | >>> | 2 | Positive | 8,0 % |
| | (172) | Immucor | >>> | 8 | Positive | 32 % |
| | (173) | Sanguin | >>> | 7 | Positive | 28 % |
| | (183) | Immunodiagnostic Systems | >>> | 1 | Positive | 4,0 % |
| | Total per sample: n = 25 | | | Success: 100 % | | |
| 2 | (6) | APR | >>> | 1 | Positive | 4,0 % |
| | (14) | Bio-Rad | >>> | 2 | Positive | 8,0 % |
| | (64) | Exbio Olomouc | >>> | 2 | Positive | 8,0 % |
| | (80) | DiaMed | >>> | 2 | Positive | 8,0 % |
| | (159) | Grifols | >>> | 2 | Positive | 8,0 % |
| | (172) | Immucor | >>> | 8 | Positive | 32 % |
| | (173) | Sanguin | >>> | 7 | Positive | 28 % |
| | (183) | Immunodiagnostic Systems | >>> | 1 | Positive | 4,0 % |
| Total per sample: n = 25 | | | Success: 100 % | | | |
| Total success: 100 % | | | | | | |

| Test | | | N | Result | N _{rel} |
|---------------------------|--------------------|----------------|----|---------------|------------------|
| Sample | Group | | | | |
| (1031) Antigen s | | | | | |
| 1 | (6) APR | >>> | 1 | Positive | 5,9 % |
| | (14) Bio-Rad | >>> | 1 | Positive | 5,9 % |
| | (64) Exbio Olomouc | >>> | 1 | Positive | 5,9 % |
| | (80) DiaMed | >>> | 2 | Positive | 12 % |
| | (159) Grifols | >>> | 2 | Positive | 12 % |
| | (172) Immucor | >>> | 10 | Positive | 59 % |
| Total per sample: n = 17 | | Success: 100 % | | | |
| 2 | (6) APR | >>> | 1 | Positive | 5,9 % |
| | (14) Bio-Rad | >>> | 1 | Positive | 5,9 % |
| | (64) Exbio Olomouc | >>> | 1 | Positive | 5,9 % |
| | (80) DiaMed | >>> | 2 | Positive | 12 % |
| | (159) Grifols | >>> | 2 | Positive | 12 % |
| | (172) Immucor | >>> | 10 | Positive | 59 % |
| Total per sample: n = 17 | | Success: 100 % | | | |
| Total success: 100 % | | | | | |
| (1032) Antigen P1 | | | | | |
| 1 | (14) Bio-Rad | >>> | 3 | Positive | 14 % |
| | (64) Exbio Olomouc | >>> | 3 | Positive | 14 % |
| | (80) DiaMed | >>> | 2 | Positive | 9,1 % |
| | (159) Grifols | >>> | 3 | Positive | 14 % |
| | (172) Immucor | >>> | 5 | Positive | 23 % |
| | (173) Sanguin | >>> | 6 | Positive | 27 % |
| Total per sample: n = 22 | | Success: 100 % | | | |
| 2 | (14) Bio-Rad | >>> | 2 | Negative | 9,1 % |
| | | | 1 | Positive | 4,5 % |
| | (64) Exbio Olomouc | >>> | 3 | Negative | 14 % |
| | (80) DiaMed | >>> | 1 | Negative | 4,5 % |
| | | | 1 | Positive | 4,5 % |
| | (159) Grifols | >>> | 3 | Negative | 14 % |
| | (172) Immucor | >>> | 5 | Negative | 23 % |
| | (173) Sanguin | >>> | 6 | Negative | 27 % |
| Total per sample: n = 22 | | Success: 91 % | | | |
| Total success: 91 % | | | | | |
| (1033) Antigen Jka | | | | | |
| 1 | (14) Bio-Rad | >>> | 3 | Positive | 11 % |
| | (52) Dynex | >>> | 2 | Positive | 7,1 % |
| | (64) Exbio Olomouc | >>> | 3 | Positive | 11 % |
| | (80) DiaMed | >>> | 1 | Positive | 3,6 % |
| | (159) Grifols | >>> | 4 | Positive | 14 % |
| | (172) Immucor | >>> | 7 | Positive | 25 % |
| | (173) Sanguin | >>> | 8 | Positive | 29 % |
| Total per sample: n = 28 | | Success: 100 % | | | |
| 2 | (14) Bio-Rad | >>> | 1 | Not specified | 3,6 % |
| | | | 2 | Positive | 7,1 % |
| | (52) Dynex | >>> | 2 | Positive | 7,1 % |
| | (64) Exbio Olomouc | >>> | 3 | Positive | 11 % |
| | (80) DiaMed | >>> | 1 | Positive | 3,6 % |
| | (159) Grifols | >>> | 4 | Positive | 14 % |
| | (172) Immucor | >>> | 7 | Positive | 25 % |
| | (173) Sanguin | >>> | 8 | Positive | 29 % |
| Total per sample: n = 28 | | Success: 96 % | | | |
| Total success: 96 % | | | | | |
| (1034) Antigen Jkb | | | | | |
| 1 | (14) Bio-Rad | >>> | 2 | Positive | 7,4 % |
| | (52) Dynex | >>> | 1 | Positive | 3,7 % |
| | (64) Exbio Olomouc | >>> | 3 | Positive | 11 % |
| | (80) DiaMed | >>> | 1 | Positive | 3,7 % |
| | (159) Grifols | >>> | 4 | Positive | 15 % |
| | (172) Immucor | >>> | 7 | Positive | 26 % |
| | (173) Sanguin | >>> | 9 | Positive | 33 % |
| Total per sample: n = 27 | | Success: 100 % | | | |
| 2 | (14) Bio-Rad | >>> | 2 | Positive | 7,4 % |
| | (52) Dynex | >>> | 1 | Positive | 3,7 % |
| | (64) Exbio Olomouc | >>> | 3 | Positive | 11 % |
| | (80) DiaMed | >>> | 1 | Positive | 3,7 % |
| | (159) Grifols | >>> | 4 | Positive | 15 % |
| | (172) Immucor | >>> | 7 | Positive | 26 % |

EQA round: PAT1/21 - Direct Antiglobulin Test

Deadline: 04.06.2021

| Test | Sample | Group | N | Result | N _{rel} |
|---------------------------|--------------------------|--------------------|----------------|------------|------------------|
| | 2 | (173) Sanguin | >>> | 9 Positive | 33 % |
| | Total per sample: n = 27 | | Success: 100 % | | |
| | Total success: 100 % | | | | |
| (1035) Antigen Lea | | | | | |
| | 1 | (14) Bio-Rad | >>> | 1 Negative | 5,3 % |
| | | | | 1 Positive | 5,3 % |
| | | (64) Exbio Olomouc | >>> | 1 Negative | 5,3 % |
| | | | | 1 Positive | 5,3 % |
| | | (80) DiaMed | >>> | 1 Negative | 5,3 % |
| | | (159) Grifols | >>> | 3 Negative | 16 % |
| | | (172) Immucor | >>> | 6 Negative | 32 % |
| | | | | 1 Positive | 5,3 % |
| | | (173) Sanguin | >>> | 4 Negative | 21 % |
| | Total per sample: n = 19 | | Success: 84 % | | |
| | 2 | (14) Bio-Rad | >>> | 1 Negative | 5,3 % |
| | | | | 1 Positive | 5,3 % |
| | | (64) Exbio Olomouc | >>> | 2 Negative | 11 % |
| | | (80) DiaMed | >>> | 1 Positive | 5,3 % |
| | | (159) Grifols | >>> | 3 Negative | 16 % |
| | | (172) Immucor | >>> | 7 Negative | 37 % |
| | | (173) Sanguin | >>> | 3 Negative | 16 % |
| | | | | 1 Positive | 5,3 % |
| | Total per sample: n = 19 | | Success: 84 % | | |
| | Total success: 74 % | | | | |
| (1036) Antigen Leb | | | | | |
| | 1 | (14) Bio-Rad | >>> | 1 Negative | 5,3 % |
| | | | | 1 Positive | 5,3 % |
| | | (64) Exbio Olomouc | >>> | 2 Positive | 11 % |
| | | (80) DiaMed | >>> | 1 Positive | 5,3 % |
| | | (159) Grifols | >>> | 3 Positive | 16 % |
| | | (172) Immucor | >>> | 7 Positive | 37 % |
| | | (173) Sanguin | >>> | 4 Positive | 21 % |
| | Total per sample: n = 19 | | Success: 95 % | | |
| | 2 | (14) Bio-Rad | >>> | 2 Negative | 11 % |
| | | (64) Exbio Olomouc | >>> | 2 Positive | 11 % |
| | | (80) DiaMed | >>> | 1 Negative | 5,3 % |
| | | (159) Grifols | >>> | 3 Positive | 16 % |
| | | (172) Immucor | >>> | 7 Positive | 37 % |
| | | (173) Sanguin | >>> | 4 Positive | 21 % |
| | Total per sample: n = 19 | | Success: 84 % | | |
| | Total success: 84 % | | | | |